CN111543639A - Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver - Google Patents
Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver Download PDFInfo
- Publication number
- CN111543639A CN111543639A CN201910110144.5A CN201910110144A CN111543639A CN 111543639 A CN111543639 A CN 111543639A CN 201910110144 A CN201910110144 A CN 201910110144A CN 111543639 A CN111543639 A CN 111543639A
- Authority
- CN
- China
- Prior art keywords
- strain
- lactic acid
- lactobacillus
- acid bacteria
- cgmcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 164
- 239000004310 lactic acid Substances 0.000 title claims abstract description 82
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 82
- 241000894006 Bacteria Species 0.000 title claims abstract description 60
- 210000004185 liver Anatomy 0.000 title claims abstract description 50
- 235000013305 food Nutrition 0.000 title claims abstract description 24
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 230000002633 protecting effect Effects 0.000 title claims abstract description 15
- 230000001580 bacterial effect Effects 0.000 claims abstract description 24
- 241000186660 Lactobacillus Species 0.000 claims abstract description 22
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 22
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 22
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 22
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 22
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 20
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 20
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 19
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 19
- 238000004321 preservation Methods 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 26
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 244000005700 microbiome Species 0.000 claims description 6
- 239000006186 oral dosage form Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 235000013351 cheese Nutrition 0.000 claims description 2
- 235000015218 chewing gum Nutrition 0.000 claims description 2
- 229940112822 chewing gum Drugs 0.000 claims description 2
- 235000016213 coffee Nutrition 0.000 claims description 2
- 235000013353 coffee beverage Nutrition 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 235000013618 yogurt Nutrition 0.000 claims description 2
- 235000020124 milk-based beverage Nutrition 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 26
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 21
- 108010082126 Alanine transaminase Proteins 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 125000003158 alcohol group Chemical group 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 230000003247 decreasing effect Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 229960003180 glutathione Drugs 0.000 description 13
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 12
- 108010024636 Glutathione Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 208000006454 hepatitis Diseases 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000004930 Fatty Liver Diseases 0.000 description 9
- 102000006587 Glutathione peroxidase Human genes 0.000 description 9
- 108700016172 Glutathione peroxidases Proteins 0.000 description 9
- 208000010706 fatty liver disease Diseases 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- 208000018191 liver inflammation Diseases 0.000 description 8
- 231100000240 steatosis hepatitis Toxicity 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 238000009629 microbiological culture Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 208000002353 alcoholic hepatitis Diseases 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 108010094028 Prothrombin Proteins 0.000 description 3
- 102100027378 Prothrombin Human genes 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019543 dairy drink Nutrition 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 229940039716 prothrombin Drugs 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000191996 Pediococcus pentosaceus Species 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000009982 effect on human Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001865 kupffer cell Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 241000272041 Naja Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 235000021109 kimchi Nutrition 0.000 description 1
- -1 lipid peroxides Chemical class 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides food compositions and pharmaceutical compositions containing lactic acid bacteria strains for protecting the liver. The present invention provides an isolated lactic acid bacterial strain selected from at least one of the following: lactobacillus plantarum TSP05 strain, Lactobacillus fermentum TSF331 strain, and Lactobacillus reuteri TSR332 strain. The lactobacillus strain has liver protecting function, and is in the form of food composition or pharmaceutical composition.
Description
Technical Field
The present invention relates to a food composition and a pharmaceutical composition, and more particularly to a food composition and a pharmaceutical composition comprising a lactic acid bacterial strain having a hepatoprotective function.
Background
The liver is the largest organ of the human body and is responsible for very important tasks including: 1. the circulation function is as follows: bringing blood from the portal artery to the systemic circulation, the reticuloendothelial system (reticuloendothelial system) of the blood is involved in immune mechanism and stores the blood, and has the function of regulating blood volume; 2. the excretion function is as follows: bile is formed and discharged into the intestine, combined with bile pigments (bilirubin conjugates) secreted by the liver, cholesterol (cholestrol), cholic acid (cholic acid) to form bile salts, and substances separated from the blood by the liver cells, such as heavy metals, dyes (brolsulein), alkaline phosphatase (alkalophatase), and the like, can be excluded; 3. metabolic function: participate in the metabolism of carbohydrates, proteins, fats, minerals and vitamins, and produce heat; 4. the defending function and the detoxifying function: the Kupffer cell (Kupffer cell) can remove foreign matters in blood through phagocytosis, reduce the toxicity of noxious substances through combination, methylation, oxidation and reduction, and then is taken out of a body through an excretion system; also has the function of removing ammonia from blood, in particular ammonia molecules absorbed via portal vein; and 5. hematopoietic and blood clotting functions: the liver has hematopoietic function in embryonic stage, and also in abnormal cases after adult life, and additionally, blood coagulation substances such as fibrinogen, prothrombin and heparin, and destruction of old red blood cells can be produced. Therefore, it is very important for the human body to maintain good liver function.
Ethanol (alcohol) is an important cause of hepatitis. Alcoholic hepatitis is generally caused after long-term alcoholism. Symptoms of alcoholic hepatitis include discomfort, enlarged liver, ascites tumor, and high liver function index value. Milder alcoholic hepatitis only has elevated liver function index values. The severe symptoms include severe liver inflammation, jaundice, increased prothrombin time, and liver failure. In the most severe cases, the patient may be confused, accompanied by an increase in the bilirubin level and prolonged prothrombin time. In these severe cases, mortality rates of 50% occur within 30 days after symptoms appear.
The anatomical appearance of the liver in non-alcoholic steatohepatitis is very similar to that of alcoholic hepatitis (fat droplets, inflamed cells), but these patients have no history of alcohol abuse. One relatively mild and similar disease is fatty liver disease (steatoshiftis), abbreviated as "fatty liver". Fatty liver is also found in 80% of patients with obesity. The anatomy of the liver of these patients can see fat droplets everywhere in the liver, but there is no sign of inflammation. Fatty liver may further develop into hepatitis, cirrhosis, and even hepatocellular carcinoma.
A few strains of lactic acid bacteria have been found to have liver-protecting activity through experimental procedures and have been confirmed. It is emphasized that the function of lactic acid bacteria on physical health lies in the specificity of the strains (strains) rather than the species (species), and that such strains with a particular effect on human health are called functional probiotics (microorganisms for the evaluation of probiotics in foods; Report of joint FAO/WHO working group on drying peptides for the evaluation of probiotics in foods; London Ontario, Canada April 30and May 1,2002: 1-7).
In summary, there is an urgent need to develop a nutritional supplement that is safe and can be used for a long time to protect the liver. Since lactic acid bacteria are generally safe, it is a very important objective to find out a lactic acid bacteria strain having liver protecting function.
Disclosure of Invention
The present invention provides a food composition and a pharmaceutical composition containing a lactic acid bacterium strain, which can protect the liver and reduce liver inflammation and fatty liver.
The food composition containing lactobacillus strains according to an embodiment of the present invention comprises lactobacillus strains having liver protecting activity, wherein the lactobacillus strains are selected from at least one of the following isolated lactobacillus strains: lactobacillus plantarum TSP05 strain with preservation number of CGMCC No. 16710; lactobacillus fermentum TSF331 strain with preservation number of CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No.15528, wherein the Lactobacillus strains are all preserved in the common microorganism center of China Committee for culture Collection of microorganisms; and a physiologically acceptable excipient, diluent or carrier.
In another embodiment of the present invention, the pharmaceutical composition comprises a lactic acid bacterial strain having an effect of protecting liver activity, wherein the lactic acid bacterial strain is selected from at least one isolated lactic acid bacterial strain selected from the group consisting of: lactobacillus plantarum TSP05 strain with preservation number of CGMCC No. 16710; lactobacillus fermentum TSF331 strain with preservation number of CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No.15528, wherein the Lactobacillus strains are all preserved in the common microorganism center of China Committee for culture Collection of microorganisms; and a pharmaceutically acceptable excipient, diluent or carrier.
The purpose, technical content, features and effects of the present invention will be more readily understood by the following detailed description of the embodiments taken in conjunction with the accompanying drawings.
Drawings
FIG. 1 is a graph showing the results of animal experiments with alanine Aminotransferase (ALT) in the serum of groups of mice fed with the lactic acid bacteria strain of the present invention.
FIG. 2 is a graph showing the results of animal experiments on glutamic-oxaloacetic transaminase (AST) in the serum of various groups of mice fed with the lactic acid bacterium strain of the present invention.
FIG. 3 shows the results of animal experiments with triglycerides in the serum of various groups of mice fed with the lactic acid bacteria strain of the present invention.
FIG. 4 is the results of animal experiments on total cholesterol in serum of various groups of mice fed with the lactic acid bacterium strain of the present invention.
FIG. 5 is a graph showing the results of animal experiments on triglycerides in the livers of groups of mice fed with the lactic acid bacterium strain of the present invention.
FIG. 6 is the results of animal experiments with glutathione in the livers of groups of mice fed with the lactic acid bacterium strain of the present invention.
FIG. 7 is a graph showing the results of animal experiments on glutathione peroxidase activity in the livers of groups of mice fed with the lactic acid bacterium strain of the present invention.
Microbial preservation for patent procedure:
TSP05
The preservation date is as follows: 11/2018, 05/month;
the preservation unit: china general microbiological culture Collection center (CGMCC);
the address of the depository: xilu No.1 Hospital No. 3, the institute of microbiology, China academy of sciences, Beijing, Chaoyang
The preservation number is: CGMCC No. 16710;
and (3) classification and naming: lactobacillus plantarum (Lactobacillus plantarum);
(II) TSF331
The preservation date is as follows: 29 months 03, 2018;
the preservation unit: china general microbiological culture Collection center (CGMCC);
the address of the depository: xilu No.1 Hospital No. 3, the institute of microbiology, China academy of sciences, Beijing, Chaoyang
The preservation number is: CGMCC No. 15527;
and (3) classification and naming: lactobacillus fermentum;
(III) TSR332
The preservation date is as follows: 29 months 03, 2018;
the preservation unit: china general microbiological culture Collection center (CGMCC);
the address of the depository: xilu No.1 Hospital No. 3, the institute of microbiology, China academy of sciences, Beijing, Chaoyang
The preservation number is: CGMCC No. 15528;
and (3) classification and naming: lactobacillus reuteri.
Detailed Description
The following detailed description of the various embodiments of the invention, taken in conjunction with the accompanying drawings, is provided by way of illustration. Aside from the detailed description, this invention is capable of broad application in other embodiments and many variations and modifications of the invention will be apparent to those skilled in the art upon reading the specification and understanding the present invention. In the description of the specification, numerous specific details are set forth in order to provide a more thorough understanding of the invention; however, the present invention may be practiced without some or all of these specific details. In other instances, well-known steps or elements have not been described in detail so as not to unnecessarily obscure the present invention. The same or similar elements in the drawings will be denoted by the same or similar symbols. It is noted that the drawings are merely schematic and do not represent actual sizes or quantities of elements, and some details may not be fully drawn for clarity of drawing.
The freeze-dried culture of the lactobacillus strain is preserved in the common microorganism center of China Committee for culture Collection of microorganisms (CGMCC, institute No. 3 of Microbiol No.1 of Naja district, Beijing, China academy of sciences, 100101). The details of the deposit are shown in table 1:
TABLE 1 deposited data of Lactobacillus strains
| Name of Strain | Classification | Deposit number | Date of storage |
| TSP05 | Lactobacillus plantarum | CGMCC No.16710 | 11/2018/11/05 |
| TSF331 | Lactobacillus fermentum | CGMCC No.15527 | 29/03/2018 |
| TSR332 | Lactobacillus reuteri | CGMCC No.15528 | 29/03/2018 |
Of the three deposited lactic acid bacteria listed in Table 1, Lactobacillus plantarum (Lactobacillus plantarum) TSP05 strain, Lactobacillus fermentum (Lactobacillus fermentum) TSF331 strain, and Lactobacillus reuteri (Lactobacillus reuteri) TSR332 strain were found to have the benefit of protecting the liver from liver inflammation.
The present invention comprises a lactic acid bacterial strain having an effect of protecting liver activity, the lactic acid bacterial strain being selected from at least one of the following isolated lactic acid bacterial strains: lactobacillus plantarum TSP05 strain with preservation number of CGMCC No. 16710; lactobacillus fermentum TSF331 strain with preservation number of CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No.15528, wherein the Lactobacillus strains are all preserved in China general microbiological culture Collection center (CGMCC); and a physiologically acceptable excipient, diluent or carrier, or a pharmaceutical composition comprising a pharmaceutically acceptable excipient, diluent or carrier. Wherein the lactic acid bacteria strain is active strain.
In the case of food compositions, the physiologically acceptable excipient, diluent or carrier may be a food product. For example, the food product may include, but is not limited to, a dairy drink, tea, coffee, chewing gum, dentrifices (e.g., buccal tablets, chewable lozenges, soft candies, etc.), or combinations thereof, wherein the dairy drink may include fermented milk, yogurt, cheese, or dairy drink milk powder, and the like. The pharmaceutical composition may be in an oral dosage form. For example, oral dosage forms can be tablets, capsules, solutions, powders, and the like.
In the case of food or pharmaceutical compositions, the lactic acid bacterial strain is present in an amount of 106Above CFU; preferably, the number of lactic acid bacteria strains is 1010Above CFU.
It is noted that the literature indicates that not all strains of lactic acid bacteria of the same species are helpful for protecting the liver. For example, Xingrong Zhao et al (PLoS ONE 7(2): e30696.doi:10.1371/journal. po.0030696) used a high fat diet to induce an obese mouse model to investigate the efficacy of lactic acid bacterial strains on high fat diet induced obesity and fatty liver. The test results showed that only Pediococcus pentosaceus (Pediococcus pentosaceus) strain LP28 could reduce weight gain and triglyceride and cholesterol in the liver, but that lactobacillus plantarum (lactobacillus plantarum) SN13T strain and the heat-killed LP28 strain were not effective. Alternatively, Yi Qiao et al (Journal of functional foods 14(2015) 424) 434) studied the effect of different L3 and L10 strains of Lactobacillus reuteri on inflammation and fat storage in a mouse model of obesity on high fat diet. The test results showed that only the L3 strain had the effect of improving liver hypertrophy and liver steatosis, while the L10 strain had no effect. Therefore, the bacterial strains claimed by the invention only comprise Lactobacillus plantarum TSP05 (with the preservation number of CGMCCNo.16710) and Lactobacillus fermentum TSF331 (with the preservation number of CGMCCNo.15527) which are preserved in China general microbiological culture Collection center (CGMCC); and Lactobacillus reuteri TSR332 (accession number cgmccno.15528), not widely including all the same species of lactic acid bacteria strains.
Example 1: morphological and general Properties of Lactobacillus strains with hepatoprotective function
The taxonomical characteristics of the strain were confirmed based on the results of 16S rDNA sequence analysis and analysis by the API bacterial identification system. The morphological and general characteristics of the above strains are detailed in table 2:
table 2 morphological and general characterization of the lactic acid bacteria strains of the invention
Example 2: collection, culture and preservation of lactic acid bacteria strains
The lactic acid bacterial strains collected by the applicant were stored at-80 ℃ with 20% glycerol. Before use, the mixture was activated twice (24 hours) at 37 ℃ with MRS broth (DIFCO) containing 0.05% cysteine. Lactobacillus strains used for research, including Lactobacillus plantarum (Lactobacillus plantarum) TSP05 strain, Lactobacillus fermentum (Lactobacillus fermentum) TSF331 strain, and Lactobacillus reuteri (Lactobacillus reuteri) TSR332 strain, wherein the source of Lactobacillus plantarum (Lactobacillus plantarum) TSP05 strain is kimchi; the sources of the Lactobacillus fermentum TSF331 strain and the Lactobacillus reuteri TSR332 strain were the intestinal tracts of healthy chickens.
Example 3: animal test of lactic acid bacteria strain with liver protecting function
Under the condition of alcohol diet, C57BL/6N mice are used as a research mode to evaluate the influence of the lactobacillus strains on the oxidative damage of liver tissues of the mice induced by the alcohol, and liver function indexes such as alanine Aminotransferase (ALT) and aspartate Aminotransferase (AST) in serum and the relation between the content of triglyceride in the liver and fatty liver are measured. Aspartate Aminotransferase (AST) is also present in the liver, myocardium, muscle, and within erythrocytes; glutamate pyruvate transaminase (ALT) is mainly present in hepatocytes. When these cells are necrotized and destroyed by various causes, intracellular transaminase is released into blood, so that there is a possibility that AST value is increased in hepatitis, myocardial infarction, muscle inflammation or hemolysis, and the degree of cell destruction can be estimated by examining the increase of these enzymes by blood drawing. Similarly, elevated ALT levels are the result of liver inflammation. For the liver, when the liver cells are damaged by drugs, alcohol, virus, hypoxia, etc., the damaged condition of liver cells can be known by examining the AST value or ALT value rise through blood drawing test.
First, 44C 57BL/6N male mice were divided into six groups, namely, a control group (control group), an alcohol group (alcohol), an alcohol plus TSP05 strain group (alcohol + TSP05), an alcohol plus TSF331 and TSR332 strain group (alcohol + TSF331+ TSR332), an alcohol plus TSP05, a TSF331 and TSR332 strain group (alcohol + Mix-LAB), and a TSP05, TSF331 and TSR332 strain group (Mix-LAB). The control group and TSP05, TSF331 and TSR332 strain groups were fed freely on Lieber-DeCarli fluid normal feed, and the alcohol group and alcohol plus lactic acid bacteria strain groups were fed freely on Lieber-DeCarli fluid alcohol feed. The control group and the alcohol group were fed with secondary water through a gastric tube once a day, and the TSP05, TSF331 and TSR332 strains and the alcohol plus lactic acid bacteria strains were fed with the lactic acid bacteria strain samples for four weeks. During the experiment, blood was collected every two weeks and analyzed for alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), triglyceride and total cholesterol, and mouse liver tissue was collected after sacrifice at week 4 for liver triglyceride, Glutathione (Glutathione) content and Glutathione peroxidase (Glutathione peroxidase) analysis.
Glutathione is an important antioxidant substance in the human body, and is often called "antioxidant mother", but gradually decreases with the influence of aging, irregular life, bad eating habits, and the like. The concentration of glutathione in the liver may indicate its antioxidant capacity. Glutathione peroxidase is a general term for an enzyme family with peroxidase activity, and the main biological effect of the glutathione peroxidase is to play a role in detoxification in organisms and prevent the organisms from being damaged by oxidation. Glutathione peroxidase is a enzyme that reduces lipid peroxides to the corresponding alcohol and reduces free hydrogen peroxide to water, while catalyzing the conversion of glutathione to the oxidized form.
Glutathione (Glutathione, GSH) concentration assay:
according to the QuantiChromTM glutamthione Assay Kit operating manual. Adding phosphate buffer solution into liver tissue at a ratio of 1:4, homogenizing, collecting 200 μ L of homogenized solution, centrifuging at 4 deg.C at 14,000rpm for 10 min, and collecting supernatant. Then configure Blank and calibration: mu.L (ddH)2O and 100. mu.L Calibrator were added to a 96-well plate, followed by 200. mu.L ddH2O addition of Blank andmixing in Calibrator well. mu.L of the LSample was then mixed with 120. mu.L of Reagent A in a 1.5mL centrifuge tube and centrifuged at 14,000 min for 5 min if turbidity was present. Next, 200. mu.L of the Sample/Reagent A mixture was added to the 96-well plate, 100. mu.L of the Reagent B was added thereto and mixed well by tapping the well plate, and after standing at room temperature for 25 minutes, the absorbance of OD412nm was measured and the glutathione concentration was calculated by the following equation:
GSH(μM)＝[(ODsample-ODBlank)/(ODCalibrator-ODBlank)]×100×n
wherein ODsampleIs the absorbance, OD, of SampleBlankIs the absorbance, OD, of BlankCalibratorThe absorbance of Calibrator and n is the dilution factor.
Hereinafter, referring to FIGS. 1 to 7, the results of animal experiments using the lactic acid bacteria strain having the effect of protecting liver activity according to the present invention will be described. FIG. 1 is a graph showing the results of animal experiments with alanine Aminotransferase (ALT) in the serum of groups of mice fed with the lactic acid bacteria strain of the present invention. As can be seen from the results in fig. 1, the alcohol group was significantly higher (p < 0.01) at week 2 (2W) and week 4 (4W) compared to the control group, and it was shown that alcohol caused an increase in the liver inflammation index ALT as indicated by # in fig. 1. While feeding the lactic acid bacteria strains of the present invention significantly reduced ALT values, wherein the symbols in figure 1 indicate that the group of alcohol plus lactic acid bacteria strains of the present invention at the same time point showed a significant or very significant reduction in the alcohol-induced increase in the liver inflammation index ALT (p, p < 0.05;. p, p < 0.01). At week 2, the ALT value of TSP05 group was decreased from 57 to 36, the ALT value of TSF331+ TSR332 group was decreased from 57 to 33, and the ALT value of TSP05+ TSF331+ TSR332 group was decreased from 57 to 28; at week 4, the ALT value of TSP05 group was decreased from 49 to 35, the ALT value of TSF331+ TSR332 group was decreased from 49 to 31, and the ALT value of TSP05+ TSF331+ TSR332 group was decreased from 49 to 25. The three groups fed with the lactobacillus strains of the invention achieve significant differences, wherein the mixed TSP05, TSF331 and TSR332 strains have better use effects. There was no significant difference between the groups fed with the lactic acid bacteria strain of the present invention in the second and fourth weeks.
Please refer to fig. 2, which shows the results of animal experiments on glutamic-oxaloacetic transaminase (AST) in serum of various groups of mice after feeding the lactobacillus strains of the present invention. As can be seen from the results shown in FIG. 2, the ALT level in the serum was significantly or significantly higher in both the alcohol groups at weeks 2 and 4 (#, p < 0.01; #, p < 0.05), and thus, the liver inflammation index AST was increased by alcohol. Feeding the lactic acid bacteria strain of the present invention can significantly reduce the AST value. At week 2, the AST value of TSP05 group decreased from 73 to 59, the AST rise by alcohol was significantly reduced compared to the alcohol group (, p < 0.05), the AST value of TSF331+ TSR332 group decreased from 73 to 63, the AST value of TSP05+ TSF331+ TSR332 group decreased from 73 to 54, and there was a very significant decrease compared to the alcohol group (, p < 0.01); at week 4, the AST value of TSP05 group decreased from 89 to 76, the AST value of TSF331+ TSR332 group decreased from 89 to 72, and the AST value of TSP05+ TSF331+ TSR332 group decreased from 89 to 66. The three groups fed with the lactic acid bacteria strain of the present invention all had the effect of reducing AST, and among them, the effect of using three strains of TSP05, TSF331 and TSR332 in combination was better. There was no significant difference between the groups fed with the lactic acid bacteria strain of the present invention in the second and fourth weeks.
Please refer to fig. 3, which shows the results of animal experiments on triglycerides in the serum of various groups of mice fed with the lactobacillus strain of the present invention. At week 2, the triglyceride values in each group were significantly higher than those measured at week 0 (0W), with the alcohol group (alcohol group) being significantly higher than the control group, as indicated by the # in fig. 3, and at week 4, the alcohol group was different but not significantly higher than the control group (p ═ 0.08). The TSP05 group, the TSF331+ TSR332 group and the TSP05+ TSF331+ TSR332 group can reduce triglyceride values at 2 weeks and 4 weeks, wherein the TSF331+ TSR332 group has better effect of reducing triglyceride in serum, and the significant difference (p is less than 0.05) is achieved.
Please refer to fig. 4, which shows the results of animal experiments on total cholesterol in serum of various groups of mice fed with the lactobacillus strain of the present invention. At week 2, the total cholesterol values were higher for each group than for week 0, with no significant difference between groups. At week 4, the alcohol-fed groups were not significantly different but were lower than the alcohol-unfed groups (control group and Mix-LAB group), indicating that the lactic acid bacterium strain of the present invention did not change the serum cholesterol concentration within week 4.
Referring to fig. 5, which is a result of an animal test of triglycerides in livers of respective groups of mice fed with the lactic acid bacterium strain of the present invention, wherein symbols, # and # indicate that the respective groups are significantly different from the control group, and symbols # and # indicate that the groups fed with alcohol plus the lactic acid bacterium strain of the present invention are significantly different from the alcohol group. From the results of fig. 5, it is understood that the triglyceride concentration (μ M/g) in the liver of the alcohol group was significantly increased from 39 μ M/g to 76 μ M/g. The feeding of the lactobacillus strain of the invention can obviously reduce the triglyceride concentration in the liver, wherein the triglyceride concentration in the liver of TSP05 group is reduced to 50 mu M/g, the triglyceride concentration in the liver of TSF331+ TSR332 group is reduced to 49 mu M/g, and the triglyceride concentration in the liver of TSP05+ TSF331+ TSR332 group is reduced to 51 mu M/g, which reach a significant difference, thereby avoiding the formation of fatty liver. There were no significant differences between the groups fed with the lactic acid bacteria strains of the present invention.
Referring to fig. 6, which is the results of animal experiments on glutathione in livers of various groups of mice fed with the lactic acid bacterium strain of the present invention, symbols # and # indicate that the groups are significantly different from the control group, and symbol # indicates that the group fed with alcohol plus the lactic acid bacterium strain of the present invention is significantly different from the alcohol group. From the results of fig. 6, it was found that the glutathione concentration in the liver was significantly decreased in the alcohol group from 925 μ M/g to 590 μ M/g, indicating that alcohol causes oxidative stress. The concentration of glutathione in the liver can be obviously improved by feeding the groups of the lactobacillus strains, and the three groups have the effect of improving the concentration of glutathione so as to reduce the oxidation pressure of the liver, wherein the effect of mixing three strains TSP05, TSF331 and TSR332 is better.
Referring to fig. 7, which is the result of animal experiments on glutathione peroxidase activity in livers of respective groups of mice fed with the lactic acid bacterium strain of the present invention, wherein symbols are marked as very significant differences between the respective groups and the control group, and symbols # indicate that the groups fed with alcohol plus the lactic acid bacterium strain of the present invention are very significant differences between the alcohol group. From the results shown in fig. 7, it can be seen that the glutathione peroxidase activity in the liver of the alcohol group was not significantly changed compared to the control group, and the group fed with the lactobacillus strain of the present invention can significantly increase the glutathione peroxidase activity in the liver, thereby increasing the antioxidant ability.
In combination with the above test results, the lactic acid bacteria strain-containing food composition and pharmaceutical composition of the present invention can protect the liver and prevent liver inflammation and fatty liver, and can improve the antioxidant ability of the liver to prevent the liver from being damaged by the oxidative stress caused by alcohol. The invention provides a lactic acid bacteria strain which has no side effect on human body and can protect liver as a new choice for protecting liver.
The above-mentioned embodiments are merely illustrative of the technical spirit and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the content of the present invention and to implement the same, so that the scope of the present invention should not be limited by the above-mentioned embodiments, and that all equivalent changes and modifications made in the spirit of the present invention should be covered by the scope of the present invention.
Claims (13)
1. A food composition comprising a lactic acid bacterial strain comprising:
a lactic acid bacterial strain having an effect of protecting liver activity, the lactic acid bacterial strain being selected from at least one of the following isolated lactic acid bacterial strains: lactobacillus plantarum TSP05 strain with preservation number of CGMCCNo.16710; lactobacillus fermentum (Lactobacillus fermentum) TSF331 strain with preservation number of CGMCCNo.15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No.15528, wherein the Lactobacillus strains are all preserved in the common microorganism center of China Committee for culture Collection of microorganisms; and
a physiologically acceptable excipient, diluent or carrier.
2. The lactic acid bacteria strain-containing food composition according to claim 1, wherein the lactic acid bacteria strain comprises Lactobacillus plantarum TSP05 strain with accession number CGMCC No. 16710.
3. The lactic acid bacteria strain-containing food composition according to claim 1, wherein the lactic acid bacteria strain comprises the Lactobacillus fermentum TSF331 strain having the accession number CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No. 15528.
4. The lactic acid bacteria strain-containing food composition according to claim 1, wherein the lactic acid bacteria strain comprises Lactobacillus plantarum TSP05 strain, accession number CGMCC No. 16710; lactobacillus fermentum TSF331 strain with preservation number of CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No. 15528.
5. The lactic acid bacterial strain-containing food composition according to claim 1, wherein the lactic acid bacterial strain is an active strain.
6. A lactic acid bacteria strain-containing food composition according to claim 1 wherein the excipient, diluent or carrier is a food product.
7. The lactic acid bacteria strain-containing food composition of claim 6, wherein the food product comprises fermented milk, yogurt, cheese, milk drink powder, tea, coffee, chewing gum, dentrifice, or a combination thereof.
8. A pharmaceutical composition comprising a lactic acid bacterial strain, comprising:
a lactic acid bacterial strain having an effect of protecting liver activity, the lactic acid bacterial strain being selected from at least one of the following isolated lactic acid bacterial strains: lactobacillus plantarum TSP05 strain with preservation number of CGMCCNo.16710; lactobacillus fermentum (Lactobacillus fermentum) TSF331 strain with preservation number of CGMCCNo.15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No.15528, wherein the Lactobacillus strains are all preserved in the common microorganism center of China Committee for culture Collection of microorganisms; and
a pharmaceutically acceptable excipient, diluent or carrier.
9. The lactic acid bacteria strain-containing pharmaceutical composition according to claim 8, wherein the lactic acid bacteria strain comprises Lactobacillus plantarum TSP05 strain with accession number CGMCC No. 16710.
10. The lactic acid bacteria strain-containing pharmaceutical composition according to claim 8, wherein the lactic acid bacteria strain comprises the Lactobacillus fermentum TSF331 strain having the accession number CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No. 15528.
11. The lactic acid bacteria strain-containing pharmaceutical composition according to claim 8, wherein the lactic acid bacteria strain comprises Lactobacillus plantarum TSP05 strain, accession number CGMCC No. 16710; lactobacillus fermentum TSF331 strain with preservation number of CGMCC No. 15527; and Lactobacillus reuteri TSR332 with the preservation number of CGMCC No. 15528.
12. The lactic acid bacteria strain-containing pharmaceutical composition according to claim 8, wherein the lactic acid bacteria strain is an active strain.
13. The lactic acid bacterial strain-containing pharmaceutical composition according to claim 8, which is an oral dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910110144.5A CN111543639A (en) | 2019-02-11 | 2019-02-11 | Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910110144.5A CN111543639A (en) | 2019-02-11 | 2019-02-11 | Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111543639A true CN111543639A (en) | 2020-08-18 |
Family
ID=71997984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910110144.5A Pending CN111543639A (en) | 2019-02-11 | 2019-02-11 | Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111543639A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113046274A (en) * | 2021-04-26 | 2021-06-29 | 江南大学 | Lactobacillus reuteri for relieving gastrointestinal injury caused by capsaicin and application thereof |
| CN114107083A (en) * | 2020-08-27 | 2022-03-01 | 台湾烟酒股份有限公司 | Novel lactic acid bacteria and their use for treating or preventing diseases associated with liver damage |
| CN115039883A (en) * | 2021-02-26 | 2022-09-13 | 锦乔生物科技有限公司 | Use of Lactobacillus plantarum TSP05 isolate for reduction of purine content and uric acid levels |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102994422A (en) * | 2012-11-12 | 2013-03-27 | 北京和美科健生物技术有限责任公司 | Application of lactobacillus plantarum P-8 in improvement of alcoholic liver injury |
| JP2014008006A (en) * | 2012-06-29 | 2014-01-20 | Nagasaki Prefecture | Lactic acid bacterium, lactic acid bacterium culture solution, and pharmaceutical compositions and hepatocyte protective agents using these |
| US20140065114A1 (en) * | 2012-08-29 | 2014-03-06 | China Medical University | Use of lactobacillus for liver protection |
| CN103937716A (en) * | 2014-04-17 | 2014-07-23 | 扬州大学 | Anthropogenic lactobacilus fermentum grx07 and application thereof |
| CN105462899A (en) * | 2015-12-23 | 2016-04-06 | 江南大学 | Lactobacillus plantarum with function of relieving PFOS (Perfluorooctane Sulfonate) toxicity and application thereof |
| CN106074623A (en) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | Lactobacillus plantarum application in preparation has the product of hepatoprotective function |
| CN107151638A (en) * | 2017-05-25 | 2017-09-12 | 中驭(北京)生物工程有限公司 | One plant improvement liver function Lactobacillus plantarum ZY001 and its application in acidified milk |
| CN109182191A (en) * | 2018-09-26 | 2019-01-11 | 富乐顿生物工程科技（北京）有限公司 | A kind of spatial plant lactobacillus FH-SS18--86365L and its application with hepatoprotective effect |
-
2019
- 2019-02-11 CN CN201910110144.5A patent/CN111543639A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014008006A (en) * | 2012-06-29 | 2014-01-20 | Nagasaki Prefecture | Lactic acid bacterium, lactic acid bacterium culture solution, and pharmaceutical compositions and hepatocyte protective agents using these |
| US20140065114A1 (en) * | 2012-08-29 | 2014-03-06 | China Medical University | Use of lactobacillus for liver protection |
| CN102994422A (en) * | 2012-11-12 | 2013-03-27 | 北京和美科健生物技术有限责任公司 | Application of lactobacillus plantarum P-8 in improvement of alcoholic liver injury |
| CN103937716A (en) * | 2014-04-17 | 2014-07-23 | 扬州大学 | Anthropogenic lactobacilus fermentum grx07 and application thereof |
| CN105462899A (en) * | 2015-12-23 | 2016-04-06 | 江南大学 | Lactobacillus plantarum with function of relieving PFOS (Perfluorooctane Sulfonate) toxicity and application thereof |
| CN106074623A (en) * | 2016-07-07 | 2016-11-09 | 吉林省农业科学院 | Lactobacillus plantarum application in preparation has the product of hepatoprotective function |
| CN107151638A (en) * | 2017-05-25 | 2017-09-12 | 中驭(北京)生物工程有限公司 | One plant improvement liver function Lactobacillus plantarum ZY001 and its application in acidified milk |
| CN109182191A (en) * | 2018-09-26 | 2019-01-11 | 富乐顿生物工程科技（北京）有限公司 | A kind of spatial plant lactobacillus FH-SS18--86365L and its application with hepatoprotective effect |
Non-Patent Citations (3)
| Title |
|---|
| 刘晶等: "乳酸菌抗氧化能力研究进展", 《中国乳品工业》 * |
| 成艳波: "罗伊氏乳杆菌对组胺引起黄颡鱼肝肠损伤修复效果评价", 《水生生物学报》 * |
| 迟菲菲等: "植物乳杆菌LP1001缓解小鼠酒精性肝损伤的研究", 《中国乳品工业》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114107083A (en) * | 2020-08-27 | 2022-03-01 | 台湾烟酒股份有限公司 | Novel lactic acid bacteria and their use for treating or preventing diseases associated with liver damage |
| CN115039883A (en) * | 2021-02-26 | 2022-09-13 | 锦乔生物科技有限公司 | Use of Lactobacillus plantarum TSP05 isolate for reduction of purine content and uric acid levels |
| CN115039883B (en) * | 2021-02-26 | 2024-05-10 | 锦乔生物科技有限公司 | Use of lactobacillus plantarum TSP05 isolates to reduce purine content and uric acid levels |
| CN113046274A (en) * | 2021-04-26 | 2021-06-29 | 江南大学 | Lactobacillus reuteri for relieving gastrointestinal injury caused by capsaicin and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guerin-Danan et al. | Milk fermented with yogurt cultures and Lactobacillus casei compared with yogurt and gelled milk: influence on intestinal microflora in healthy infants | |
| Afify et al. | Antioxidant activity and biological evaluations of probiotic bacteria strains. | |
| He et al. | Antioxidant activity of prebiotic ginseng polysaccharides combined with potential probiotic Lactobacillus plantarum C88 | |
| US20140363501A1 (en) | The protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| US20160113975A1 (en) | Protective effects and application of a lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| CN111543639A (en) | Food composition and pharmaceutical composition containing lactic acid bacteria strain for protecting liver | |
| JP7267020B2 (en) | Fermented milk with inhibitory effect on blood sugar level elevation | |
| JP2019528763A (en) | Novel Lactobacillus sakei and composition containing the same | |
| US11045509B2 (en) | Tributyrin compositions and methods therefor | |
| CN111164201B (en) | Lactobacillus paracasei GKS6 for improving metabolic syndrome, use thereof, pharmaceutical composition and edible composition | |
| JPWO2018003899A1 (en) | Composition for improving renal anemia | |
| US20200330530A1 (en) | Hepatoprotection food composition and pharmaceutical composition with strains of lactic acid bacteria | |
| AU2011314299B2 (en) | Compositions and methods for augmenting kidney function | |
| JP3644500B2 (en) | Method for producing mushroom lactic acid fermented liquid and mushroom lactic acid fermented liquid produced therefrom | |
| US11723936B2 (en) | Therapeutic uses of Lactobacillus plantarum | |
| JP2003306436A (en) | Inhibitor of increased serum cholesterol level | |
| Ahmed et al. | Hypocholesterolaemic effect of probiotic yogurt enriched with barley β-glucan in rats fed on a high-cholesterol diet | |
| Rugji et al. | Prebiotic effect of D-allulose and β-glucan on whey beverage with Bifidobacterium animalis and investigation of some health effects of this functional beverage on rats | |
| US11963987B2 (en) | Hepatoprotection food composition and pharmaceutical composition with strains of lactic acid bacteria | |
| TWI499423B (en) | Use of novel lactobacillus strains in reducing alcohol liver lesion and a composition thereof | |
| US20100183576A1 (en) | Lipid-metabolism-ameliorating agent | |
| JP4011938B2 (en) | Lipid metabolism improving agent and food containing the same | |
| AU765371B2 (en) | Use of propionic bacteria for producing propionic acid and/or propionates in the colon | |
| Bhattacharyya | Emergence of probiotics in therapeutic applications | |
| Ismail et al. | Effect of Honey & Olive Oil Supplemented Bio-Yoghurt Feeding on Lipid Profile, Blood Glucose and Hematological Parameters in Rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221010 Address after: No. 2, Jingyi Road, Huai'an Economic and Technological Development Zone, Jiangsu Province Applicant after: JINQIAO BIOTECHNOLOGY CO.,LTD. Address before: 2 / F 4 / F, 17 international road, Xinshi District, Tainan City, Taiwan, China Applicant before: GLAC BIOTECH Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200818 |
|
| WD01 | Invention patent application deemed withdrawn after publication |